Literature DB >> 35323127

Animal Models in Epileptic Spasms and the Development of Novel Treatment Options.

Karlene T Barrett1, Anamika Choudhary1, Behshad Charkhand1, Morris H Scantlebury2.   

Abstract

SUMMARY: The infantile spasms (IS) syndrome is a catastrophic developmental epileptic encephalopathy syndrome characterized by an age-specific expression of epileptic spasms that are associated with extremely abnormal, oftentimes described as chaotic, interictal EEG pattern known as hypsarrhythmia. Patients with IS generally have poor neurodevelopmental outcomes, in large part because of the frequent epileptic spasms and interictal EEG abnormalities. Current first-line treatments such as adrenocorticotropic hormone or vigabatrin are often ineffective and are associated with major toxic side effects. There is therefore a need for better and safer treatments for patients with IS, especially for the intractable population. Hope is on the horizon as, over the past 10 years, there has been robust progress in the development of etiology-specific animal models of IS. These models have been used to identify potential new treatments for IS and are beginning to provide some important insights into the pathophysiological substrates for this disease. In this review, we will highlight strengths and weaknesses of the currently available animal models of IS in addition to new insights into the pathophysiology and treatment options derived from these models.
Copyright © 2022 by the American Clinical Neurophysiology Society.

Entities:  

Year:  2022        PMID: 35323127     DOI: 10.1097/WNP.0000000000000496

Source DB:  PubMed          Journal:  J Clin Neurophysiol        ISSN: 0736-0258            Impact factor:   2.177


  1 in total

1.  Validation of a Chromosome 14 Risk Haplotype for Idiopathic Epilepsy in the Belgian Shepherd Dog Found to Be Associated with an Insertion in the RAPGEF5 Gene.

Authors:  Janelle M Belanger; Tiina Heinonen; Thomas R Famula; Paul J J Mandigers; Peter A Leegwater; Marjo K Hytönen; Hannes Lohi; Anita M Oberbauer
Journal:  Genes (Basel)       Date:  2022-06-23       Impact factor: 4.141

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.